What was the primary driver of Amgen's revenue growth in Q1 2015?

Amgen's revenue growth was primarily driven by a significant increase in product sales, which rose by 12% year-over-year to $4.87 billion. This growth was bolstered by strong performance from key products including Enbrel, Prolia, XGEVA, Sensipar/Mimpara, and Epogen.

How did the restructuring plan impact Amgen's financial performance?

The restructuring plan contributed positively to Amgen's financial performance by reducing operating expenses by 5%. This led to improved profitability, with operating income increasing by 48% and net income by 51%. The company expects to continue realizing benefits from these cost-saving and efficiency improvement efforts.

What is Amgen's outlook on returning capital to shareholders?

Amgen is committed to returning capital to shareholders. In the first quarter of 2015, the company paid a quarterly dividend of $0.79 per share and repurchased $451 million of its common stock. A substantial amount, $3.4 billion, remained available under its stock repurchase program as of March 31, 2015.

What are the potential risks or competitive pressures mentioned in the filing?

The filing highlights increasing competition from biosimilars, specifically mentioning the FDA approval of Sandoz's biosimilar filgrastim (Zarxio™) and ongoing litigation. Additionally, patent expiries for key products like Neulasta® and EPOGEN® are noted as potential risks that could impact future sales.

AMGN 10-Q Quarterly Report Q1 FY2015 — Revenue, Net Income, EPS

Summary

Amgen Inc. reported strong financial results for the first quarter of 2015, demonstrating robust revenue growth and significant improvements in profitability. Total revenues increased by 11% year-over-year, reaching $5.03 billion, primarily driven by a 12% rise in product sales to $4.87 billion. This growth was fueled by strong performance across key products such as Enbrel, Prolia, XGEVA, Sensipar/Mimpara, and Epogen. Profitability saw a substantial jump, with operating income increasing by 48% to $2.02 billion and net income growing by 51% to $1.62 billion. This improved profitability is attributed to a decrease in operating expenses, largely due to the company's ongoing restructuring plan which aims to enhance efficiency and reduce costs, alongside favorable changes in the cost of sales as a percentage of revenue. Diluted Earnings Per Share (EPS) also surged by 51% to $2.11. The company continued to return capital to shareholders through dividends and share repurchases, underscoring its financial strength and commitment to shareholder value.

Financial Highlights

55 data points

Beta

Revenue

$5.03B

0.8% Gross Margin

Net Income

$1.62B

0.3% Net Margin

EPS (Diluted)

$2.11

Total Assets

$68.95B

Cash & Equivalents

$2.86B

Free Cash Flow

$1.36B

Financial Statements

Beta

Revenue	$5.03B
Cost of Revenue	$1.03B
Gross Profit	$3.84B
SG&A Expenses	$1.03B
Operating Expenses	$3.01B
Operating Income	$2.02B
Interest Expense	$252.00M
Net Income	$1.62B
EPS (Basic)	$2.13
EPS (Diluted)	$2.11
Shares Outstanding (Basic)	761.00M
Shares Outstanding (Diluted)	770.00M

Key Highlights

1Total revenues increased by 11% to $5.03 billion, driven by a 12% rise in product sales to $4.87 billion.
2Operating income surged by 48% to $2.02 billion, indicating improved operational efficiency.
3Net income grew by an impressive 51% to $1.62 billion, showcasing strong bottom-line performance.
4Diluted EPS rose by 51% to $2.11, reflecting enhanced profitability on a per-share basis.
5Operating expenses decreased by 5% due to restructuring initiatives and cost control measures.
6Key products like Enbrel, Prolia, XGEVA, Sensipar/Mimpara, and Epogen showed significant sales growth.
7The company continued its capital return strategy with a $0.79 per share dividend and active share repurchases totaling $451 million.

AMGEN INC Quarterly Report for Q1 Ended Mar 31, 2015

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions